InMed Pharmaceuticals, Inc. (IMLFF) is a Player in the Billion Dollar Cannabis Biotech Market

InMed Pharmaceuticals, Inc. (IMLFF) is a Player in the Billion Dollar Cannabis Biotech Market
InMed Pharmaceuticals, Inc. (IMLFF) is a Player in the Billion Dollar Cannabis Biotech Market

Despite the fire-breathing from Attorney-General Jefferson Beauregard Sessions III, there is a distinct feeling that marijuana has entered the mainstream now that Goldman Sachs has initiated coverage on GW Pharma (NASDAQ: GWPH). GW Pharma is the biopharmaceutical that developed the cannabinoid-derived Sativex to treat spasticity due to multiple sclerosis (MS), now approved by regulatory authorities in 29 countries. The success of GW Pharma and other pharmaceutical companies focused on cannabinoid research has produced an exciting new field with a lot of promise, cannabis biotech, and InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is staking a position in that emerging market. The Vancouver, Canada-based outfit is a pre-clinical stage biopharmaceutical company that is currently testing cannabinoid derivatives to treat epidermolysis bullosa and glaucoma and a full pipeline of other drug candidates.

Cannabinoids are turning out to be big business. GW Pharma presently has a market cap of around $3.0 billion, yet Goldman Sachs, in that initial report, intimated the company might be worth more. It set a target price of $189 on the stock, currently trading at just above $116, which would value the company at close to $5 billion. GW Pharma is set to file a New Drug Application (NDA) with the FDA in the first half of 2017 for Epidiolex, the company’s cannabis-based treatment for rarer forms of epilepsy.

Read the full article

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer


Read More
Thumbnail Photo Credit: N/A by N/A is licensed under N/A N/A